These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 31616443)

  • 21. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
    Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
    Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN loss correlates with T cell exclusion across human cancers.
    Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
    BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.
    Ganesh S; Shui X; Craig KP; Park J; Wang W; Brown BD; Abrams MT
    Mol Ther; 2018 Nov; 26(11):2567-2579. PubMed ID: 30274786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excluding T Cells: Is β-Catenin the Full Story?
    Hu-Lieskovan S; Homet Moreno B; Ribas A
    Cancer Cell; 2015 Jun; 27(6):749-50. PubMed ID: 26058073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
    Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
    Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.
    Dholakia J; Scalise CB; Katre AA; Goldsberry WN; Meza-Perez S; Randall TD; Norian LA; Novak L; Arend RC
    Gynecol Oncol; 2022 Jan; 164(1):170-180. PubMed ID: 34844776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
    Zhang H; Bi Y; Wei Y; Liu J; Kuerban K; Ye L
    Mol Cancer Ther; 2021 Jul; 20(7):1305-1315. PubMed ID: 34001635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
    Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
    Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression.
    Huang D; Wang Y; Thompson JW; Yin T; Alexander PB; Qin D; Mudgal P; Wu H; Liang Y; Tan L; Pan C; Yuan L; Wan Y; Li QJ; Wang XF
    Nat Cell Biol; 2022 Feb; 24(2):230-241. PubMed ID: 35145222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights.
    Patel S; Alam A; Pant R; Chattopadhyay S
    Front Immunol; 2019; 10():2872. PubMed ID: 31921137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
    Spranger S; Dai D; Horton B; Gajewski TF
    Cancer Cell; 2017 May; 31(5):711-723.e4. PubMed ID: 28486109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.
    Aoki T; Nishida N; Kurebayashi Y; Sakai K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Ueshima K; Minami Y; Tsurusaki M; Nakai T; Sakamoto M; Nishio K; Kudo M
    Liver Cancer; 2024 Jun; 13(3):285-305. PubMed ID: 38894812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Landscapes: β-Catenin Drives Immune Desertification.
    Dangaj D; Barras D; Coukos G
    Clin Cancer Res; 2019 May; 25(10):2943-2945. PubMed ID: 30837277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disruption of Wnt/β-catenin Pathway Elevates the Sensitivity of Gastric Cancer Cells to PD-1 Antibody.
    Li J; Zhang H; Bei S; Zhang X; Li H; Ye L; Feng L
    Curr Mol Pharmacol; 2022; 15(3):557-569. PubMed ID: 34139974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth.
    Pacella I; Cammarata I; Focaccetti C; Miacci S; Gulino A; Tripodo C; Ravà M; Barnaba V; Piconese S
    Cancer Immunol Res; 2018 Aug; 6(8):953-964. PubMed ID: 30018042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.
    Gattinoni L; Ji Y; Restifo NP
    Clin Cancer Res; 2010 Oct; 16(19):4695-701. PubMed ID: 20688898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wnt3a/β-Catenin Signaling Conditions Differentiation of Partially Exhausted T-effector Cells in Human Cancers.
    Schinzari V; Timperi E; Pecora G; Palmucci F; Gallerano D; Grimaldi A; Covino DA; Guglielmo N; Melandro F; Manzi E; Sagnotta A; Lancellotti F; Sacco L; Chirletti P; Grazi GL; Rossi M; Barnaba V
    Cancer Immunol Res; 2018 Aug; 6(8):941-952. PubMed ID: 30018041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Wnt signaling for improved glioma immunotherapy.
    Gutova M; Hibbard JC; Ma E; Natri HM; Adhikarla V; Chimge NO; Qiu R; Nguyen C; Melendez E; Aguilar B; Starr R; Yin H; Rockne RC; Ono M; Banovich NE; Yuan YC; Brown CE; Kahn M
    Front Immunol; 2024; 15():1342625. PubMed ID: 38449858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B7-H3 drives immunosuppression and Co-targeting with CD47 is a new therapeutic strategy in β-catenin activated melanomas.
    Hsu M; Martin TC; Vyas NS; Desman G; Mendelson K; Horst B; Parsons RE; Celebi JT
    Pigment Cell Melanoma Res; 2023 Sep; 36(5):407-415. PubMed ID: 37086018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.